Pharmaceutical Contract Development and Manufacturing Market by Service (Pharmaceutical, Biologics, Active Pharma Ingredients, Tablet, Capsule, Parenteral, Oral Liquid), End User (Big Pharma, Small Pharma, Generic Pharma, CRO) - Global Forecast to 2024

“The global pharmaceutical contract development and manufacturing market is projected to grow at a CAGR of 7.1%.”
The pharmaceutical contract development and manufacturing market is expected to reach USD 126.6 billion by 2024 from an estimated USD 90.0 billion in 2019, at a CAGR of 7.1%. The rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs are the primary growth factors for this market. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are expected to offer significant growth opportunities for players in this market. However, the introduction of serialization and changing trade policies between countries are major market challenges.

“The biologics manufacturing segment is expected to grow at the highest rate during the forecast period.”
On the basis of service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. The biologics manufacturing segment is projected to witness the highest growth in the pharmaceutical contract development and manufacturing market during the forecast period. Growth in this segment is largely driven by the growing generics market and the impending patent cliff in the pharmaceuticals industry, which have propelled interest toward biologics.

“The big pharma end user segment is expected to account for the largest market share in 2019.”
The big pharma end-user segment holds the largest share of the pharmaceutical contract development and manufacturing market. The emergence of new medicines and therapy forms, pricing pressure, pipeline challenges, and growing opportunities in emerging markets are factors contributing to the larger share of this segment.

“The Asia Pacific is likely to be the fastest-growing market for players operating in the pharmaceutical contract development and manufacturing market.”
Although Europe accounted for the largest share of the global pharmaceutical contract development and manufacturing market in 2018, the Asia Pacific is expected to witness the highest CAGR during the forecast period. The growth of its manufacturing sector, favorable government regulations, expansions by leading companies, increasing emphasis on off-patent drugs, and its highly skilled workforce are factors driving the growth of this regional segment.
A breakdown of the primary participants referred to for this report is provided below:
‧ By Company Type: Tier 1 (21%), Tier 2 (26%), and Tier 3 (53%)
‧ By Designation: C-level (32%), Director-level (26%), and Others (42%)
‧ By Region: North America (35%), Europe (30%), Asia Pacific (15%), Latin America (10%), and the Middle East & Africa (10%)
The prominent players in the pharmaceutical contract development and manufacturing market include Thermo Fisher Scientific (US), Catalent (US), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie (US), Aenova Group (Germany), Consort Medical plc (UK), Almac Group (UK), and Siegfried Holding AG (Switzerland).
Research Coverage:
This report analyzes the market for various pharmaceutical contract development and manufacturing services and their adoption patterns. It aims at estimating the market size and future growth potential of the global pharmaceutical contract development and manufacturing market and its service, end user, and regional segments. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, service offerings, and recent developments.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:
‧ Market Penetration: Comprehensive information on the service portfolios offered by the top players in the global pharmaceutical contract development and manufacturing market
‧ Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the global pharmaceutical contract development and manufacturing market
‧ Market Development: Comprehensive information on the lucrative emerging regions
‧ Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the global pharmaceutical contract development and manufacturing market
‧ Competitive Assessment: In-depth assessment of market ranking, growth strategies, revenue analysis, and services of leading players in the global pharmaceutical contract development and manufacturing market

TABLE OF CONTENTS

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 20
1.5 LIMITATIONS 20
1.6 STAKEHOLDERS 20
2 RESEARCH METHODOLOGY 21
2.1 RESEARCH APPROACH 21
2.1.1 SECONDARY RESEARCH 22
2.1.1.1 Key data from secondary sources 22
2.1.2 PRIMARY RESEARCH 23
2.1.2.1 Key data from primary sources 23
2.1.2.2 Breakdown of primaries 24
2.1.2.3 Key industry insights 24
2.2 MARKET SIZE ESTIMATION 25
2.3 DATA TRIANGULATION APPROACH 26
2.4 MARKET PLAYERS RANKING ANALYSIS 27
2.5 ASSUMPTIONS FOR THE STUDY 27
3 EXECUTIVE SUMMARY 28
4 PREMIUM INSIGHTS 32
4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING: MARKET OVERVIEW 32
4.2 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 33
4.3 REGIONAL MIX: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET (2019–2024) 34
4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEVELOPED VS. DEVELOPING MARKETS, 2019 VS. 2024 35
?
5 MARKET OVERVIEW 36
5.1 INTRODUCTION 36
5.2 MARKET DYNAMICS 36
5.2.1 DRIVERS 37
5.2.1.1 Growing demand for generics 37
5.2.1.2 Increasing investments in pharmaceutical R&D 38
5.2.1.3 Investments in advanced manufacturing technologies by CDMOs 39
5.2.2 OPPORTUNITIES 40
5.2.2.1 Increasing demand for biological therapies 40
5.2.2.2 Growing focus on specialty medicines 41
5.2.2.3 Growth in the nuclear medicine sector 41
5.2.2.4 Growing demand for cell and gene therapies 42
5.2.3 CHALLENGES 42
5.2.3.1 Introduction of serialization 42
5.2.3.2 Changing trade policies between countries 43
5.2.4 TRENDS 43
5.2.4.1 Increasing CDMO manufacturing footprint in Asian countries 43
5.2.4.2 CDMO industry consolidation 44
5.2.4.3 Increasing outsourcing of clinical trials to emerging markets 45
6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE 46
6.1 INTRODUCTION 47
6.2 PHARMACEUTICAL MANUFACTURING SERVICES 48
6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES 50
6.2.1.1 Need to cut costs and ensure focus on core areas leads companies to outsource API manufacturing 50
6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES 51
6.2.2.1 Parenteral/injectable manufacturing services 54
6.2.2.1.1 Need for high levels of expertise and growing drug development activity are driving the demand for contract manufacturing 54
6.2.2.2 Tablet manufacturing services 56
6.2.2.2.1 Shifting manufacturing requirements and need to streamline production processes is driving market growth 56
6.2.2.3 Capsule manufacturing services 57
6.2.2.3.1 Growth in demand for capsule formulations has ensured growth opportunities for service providers 57
6.2.2.4 Oral liquid manufacturing services 59
6.2.2.4.1 Complexities involved in oral liquid manufacturing have prompted companies to look to outsourcing 59
6.2.2.5 Other formulations 60
?
6.3 DRUG DEVELOPMENT SERVICES 62
6.3.1 DRUG SUBSTANCE COMPLEXITY AND HIGH COSTS HAVE SUPPORTED THE OUTSOURCING OF DRUG DEVELOPMENT 62
6.4 BIOLOGICS MANUFACTURING SERVICES 63
6.4.1 BIOLOGICS API MANUFACTURING SERVICES 65
6.4.1.1 The market for biologics API manufacturing is still in the emergent phase 65
6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES 66
6.4.2.1 Increasing R&D costs and process complexity have prompted the shift toward contract manufacturing 66
7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER 68
7.1 INTRODUCTION 69
7.2 BIG PHARMA 70
7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPY FORMS TO CONTRIBUTE TO THE GROWTH OF THIS MARKET 70
7.3 SMALL & MID-SIZE PHARMA 71
7.3.1 GROWING DEVELOPMENT OF BIOLOGIC DRUGS AND HIGH PRICING PRESSURE TO BOOST MARKET GROWTH 71
7.4 GENERIC PHARMACEUTICAL COMPANIES 73
7.4.1 GROWING DEMAND FOR GENERICS TO SUPPORT MARKET GROWTH 73
7.5 OTHER END USERS 74
8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION 76
8.1 INTRODUCTION 77
8.2 EUROPE 78
8.2.1 ITALY 82
8.2.1.1 Increasing focus on clinical research and the growing popularity of branded drugs are driving the demand for contract development and manufacturing 82
8.2.2 GERMANY 85
8.2.2.1 High healthcare expenditure and increased pharmaceutical production to support market growth 85
8.2.3 FRANCE 87
8.2.3.1 Presence of leading pharmaceutical companies to support market growth in France 87
8.2.4 UK 90
8.2.4.1 Growth in the generics market and the rising cost of manufacturing parenteral formulations are driving market growth 90
8.2.5 SWITZERLAND 93
8.2.5.1 Large volume of pharmaceutical production and growing scope for generics is expected to growth opportunities 93
?
8.2.6 SPAIN 95
8.2.6.1 Increase in biologics production to support market growth 95
8.2.7 REST OF EUROPE 98
8.3 NORTH AMERICA 100
8.3.1 US 104
8.3.1.1 The US dominates the North American pharmaceutical contract development and manufacturing market 104
8.3.2 CANADA 106
8.3.2.1 Growth of the emerging markets and slowdown in new product approvals will hamper market growth 106
8.4 ASIA PACIFIC 109
8.4.1 INDIA 113
8.4.1.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India 113
8.4.2 CHINA 116
8.4.2.1 Favorable government regulations are fueling market growth in China 116
8.4.3 JAPAN 119
8.4.3.1 Growing generics demand and push from the government will drive the demand for contract manufacturing of drugs 119
8.4.4 REST OF ASIA PACIFIC 122
8.5 LATIN AMERICA 125
8.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM 125
8.6 MIDDLE EAST & AFRICA 128
8.6.1 GOVERNMENT SUPPORT TO BOOST LOCAL PRODUCTION IS EXPECTED TO OFFER GROWTH OPPORTUNITIES FOR THE CONTRACT MANUFACTURERS IN THE REGION 128
9 COMPETITIVE LANDSCAPE 132
9.1 OVERVIEW 132
9.2 MARKET RANKING 133
9.2.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY KEY PLAYERS, 2018 133
9.3 COMPETITIVE LEADERSHIP MAPPING 135
9.3.1 VISIONARY LEADERS 135
9.3.2 INNOVATORS 135
9.3.3 DYNAMIC DIFFERENTIATORS 136
9.3.4 EMERGING COMPANIES 136
9.4 COMPETITIVE SITUATION AND TRENDS 137
9.4.1 PRODUCT LAUNCHES 137
9.4.2 EXPANSIONS 137
9.4.3 ACQUISITIONS 138
9.4.4 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 140
?
10 COMPANY PROFILES 142
(Business Overview, Products Offered, Recent Developments, MnM View)*
10.1 THERMO FISHER SCIENTIFIC INC. 142
10.2 CATALENT, INC. 146
10.3 LONZA GROUP LTD 151
10.4 RECIPHARM AB 156
10.5 VETTER PHARMA INTERNATIONAL GMBH 161
10.6 FAMAR HEALTH CARE SERVICES 162
10.7 ABBVIE INC. 164
10.8 AENOVA GROUP 167
10.9 CONSORT MEDICAL PLC 168
10.10 ALMAC GROUP 170
10.11 SIEGFRIED HOLDING AG 171
10.12 EVONIK INDUSTRIES AG 174
10.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 176
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
11 APPENDIX 179
11.1 INSIGHTS OF INDUSTRY EXPERTS 179
11.2 DISCUSSION GUIDE 180
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 183
11.4 AVAILABLE CUSTOMIZATIONS 185
11.5 RELATED REPORTS 185
11.6 AUTHOR DETAILS 186